In general, we found that CD36 promotes fibrosis through the PI3K-Akt pathway, while SaB inhibits the PI3K-Akt pathway-mediated fibrosis via CD36, suggesting that SaB may be a potential therapeutic for FS. Here, SH3BP5 is linked to Feingold syndrome.